906 related articles for article (PubMed ID: 31461239)
21. Heart failure re-hospitalizations and subsequent fatal events in coronary artery disease: insights from COMMANDER-HF, EPHESUS, and EXAMINE.
Ferreira JP; Cleland JG; Lam CSP; Anker SD; Mehra MR; van Veldhuisen DJ; Byra WM; La Police DA; Pitt B; Greenberg B; Zannad F
Clin Res Cardiol; 2021 Oct; 110(10):1554-1563. PubMed ID: 33686472
[TBL] [Abstract][Full Text] [Related]
22. Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial).
Korjian S; Braunwald E; Daaboul Y; Mi M; Bhatt DL; Verheugt FWA; Cohen M; Bode C; Burton P; Plotnikov AN; Gibson CM
Am J Cardiol; 2018 Dec; 122(11):1896-1901. PubMed ID: 30340765
[TBL] [Abstract][Full Text] [Related]
23. Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis.
Akao M; Yasuda S; Kaikita K; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H
Am Heart J; 2021 Jun; 236():59-68. PubMed ID: 33657403
[TBL] [Abstract][Full Text] [Related]
24. The efficacy and safety of rivaroxaban in coronary artery disease patients with heart failure and sinus rhythm: a systematic review and meta-analysis.
Xie S; Chen J; Xiong G; Li J; Wan J; Liu Y; Xu R; Zhang W
Eur J Clin Pharmacol; 2021 Oct; 77(10):1485-1494. PubMed ID: 34345970
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of vitamin-K antagonists and direct oral anticoagulants for stroke prevention in patients with heart failure and sinus rhythm: An updated systematic review and meta-analysis of randomized clinical trials.
Li W; Seo J; Kokkinidis DG; Palaiodimos L; Nagraj S; Korompoki E; Milionis H; Doehner W; Lip GYH; Ntaios G
Int J Stroke; 2023 Apr; 18(4):392-399. PubMed ID: 35689348
[TBL] [Abstract][Full Text] [Related]
26. Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial.
Hankey GJ; Eikelboom JW; Yi Q; Lees KR; Chen C; Xavier D; Navarro JC; Ranawaka UK; Uddin W; Ricci S; Gommans J; Schmidt R;
Lancet Neurol; 2012 Jun; 11(6):512-20. PubMed ID: 22554931
[TBL] [Abstract][Full Text] [Related]
27. Rivaroxaban in Peripheral Artery Disease after Revascularization.
Bonaca MP; Bauersachs RM; Anand SS; Debus ES; Nehler MR; Patel MR; Fanelli F; Capell WH; Diao L; Jaeger N; Hess CN; Pap AF; Kittelson JM; Gudz I; Mátyás L; Krievins DK; Diaz R; Brodmann M; Muehlhofer E; Haskell LP; Berkowitz SD; Hiatt WR
N Engl J Med; 2020 May; 382(21):1994-2004. PubMed ID: 32222135
[TBL] [Abstract][Full Text] [Related]
28. Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.
Kaplovitch E; Eikelboom JW; Dyal L; Aboyans V; Abola MT; Verhamme P; Avezum A; Fox KAA; Berkowitz SD; Bangdiwala SI; Yusuf S; Anand SS
JAMA Cardiol; 2021 Jan; 6(1):21-29. PubMed ID: 32997098
[TBL] [Abstract][Full Text] [Related]
29. CHA
Peacock WF; Tamayo S; Patel M; Sicignano N; Hopf KP; Yuan Z
Ann Emerg Med; 2017 May; 69(5):541-550.e1. PubMed ID: 27913059
[TBL] [Abstract][Full Text] [Related]
30. Anticoagulation Therapy and NOACs in Heart Failure.
Thomas I; EncisoSilva J; Schlueter M; Greenberg B
Handb Exp Pharmacol; 2017; 243():515-535. PubMed ID: 28233177
[TBL] [Abstract][Full Text] [Related]
31. Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.
Shah R; Hellkamp A; Lokhnygina Y; Becker RC; Berkowitz SD; Breithardt G; Hacke W; Halperin JL; Hankey GJ; Fox KA; Nessel CC; Mahaffey KW; Piccini JP; Singer DE; Patel MR;
Am Heart J; 2016 Sep; 179():77-86. PubMed ID: 27595682
[TBL] [Abstract][Full Text] [Related]
32. Major vascular events after transient ischaemic attack and minor ischaemic stroke: post hoc modelling of incidence dynamics.
Atanassova PA; Chalakova NT; Dimitrov BD
Cerebrovasc Dis; 2008; 25(3):225-33. PubMed ID: 18216464
[TBL] [Abstract][Full Text] [Related]
33. Ticagrelor in Patients with Stable Coronary Disease and Diabetes.
Steg PG; Bhatt DL; Simon T; Fox K; Mehta SR; Harrington RA; Held C; Andersson M; Himmelmann A; Ridderstråle W; Leonsson-Zachrisson M; Liu Y; Opolski G; Zateyshchikov D; Ge J; Nicolau JC; Corbalán R; Cornel JH; Widimský P; Leiter LA;
N Engl J Med; 2019 Oct; 381(14):1309-1320. PubMed ID: 31475798
[TBL] [Abstract][Full Text] [Related]
34. Stroke in Patients With Peripheral Artery Disease.
Kolls BJ; Sapp S; Rockhold FW; Jordan JD; Dombrowski KE; Fowkes FGR; Mahaffey KW; Berger JS; Katona BG; Blomster JI; Norgren L; Abramson BL; Leiva-Pons JL; Prieto JC; Sokurenko G; Hiatt WR; Jones WS; Patel MR
Stroke; 2019 Jun; 50(6):1356-1363. PubMed ID: 31092165
[TBL] [Abstract][Full Text] [Related]
35. Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry.
Schnabel RB; Ameri P; Siller-Matula JM; Diemberger I; Gwechenberger M; Pecen L; Manu MC; Souza J; De Caterina R; Kirchhof P
Europace; 2023 Aug; 25(9):. PubMed ID: 37713182
[TBL] [Abstract][Full Text] [Related]
36. Treatment of Rivaroxaban versus Aspirin for Non-disabling Cerebrovascular Events (TRACE): study protocol for a randomized controlled trial.
Yang F; Jiang W; Bai Y; Han J; Liu X; Zhang G; Zhao G
BMC Neurol; 2015 Oct; 15():195. PubMed ID: 26458895
[TBL] [Abstract][Full Text] [Related]
37. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial.
Pieske B; Patel MJ; Westerhout CM; Anstrom KJ; Butler J; Ezekowitz J; Hernandez AF; Koglin J; Lam CSP; Ponikowski P; Roessig L; Voors AA; O'Connor CM; Armstrong PW;
Eur J Heart Fail; 2019 Dec; 21(12):1596-1604. PubMed ID: 31820546
[TBL] [Abstract][Full Text] [Related]
38. Risk of subsequent disabling or fatal stroke in patients with transient ischaemic attack or minor ischaemic stroke: an international, prospective cohort study.
Hobeanu C; Lavallée PC; Charles H; Labreuche J; Albers GW; Caplan LR; Donnan GA; Ferro JM; Hennerici MG; Molina CA; Rothwell PM; Steg PG; Touboul PJ; Uchiyama S; Vicaut E; Wong KSL; Amarenco P;
Lancet Neurol; 2022 Oct; 21(10):889-898. PubMed ID: 36115361
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease.
Liang Y; Zhu J; Liu L; Anand SS; Connolly SJ; Bosch J; Guzik TJ; O'Donnell M; Dagenais GR; Fox KA; Shestakovska O; Berkowitz SD; Muehlhofer E; Keller L; Yusuf S; Eikelboom JW;
Cardiovasc Res; 2021 Feb; 117(3):942-949. PubMed ID: 32289159
[TBL] [Abstract][Full Text] [Related]
40. Adverse Clinical Outcomes and Associated Predictors in Rivaroxaban-Treated Atrial Fibrillation Patients With Renal Impairment.
Rivera-Caravaca JM; Anguita Sanchez M; Sanmartín Fernández M; Rafols C; Barón-Esquivias G; Arribas Ynsaurriaga F; Freixa-Pamias R; Lekuona Goya I; Vázquez Rodríguez JM; Pérez-Cabeza AI; Cosín-Sales J; Ureña Montilla I; Álvarez-Vieitez Blanco A; Marín F
Am J Cardiol; 2023 Sep; 203():122-127. PubMed ID: 37487406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
